ARTA
ALLO icon

A.R.T. Advisors’s Allogene Therapeutics ALLO Stock Holding History

A.R.T. Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,800
Closed -$333K – 80
2019
Q4 		$333K Buy
+12,800
New +$353K 0.02% 990

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

A.R.T. Advisors's ALLO Position: Q1 2020 in Review

A.R.T. Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2020, closing a stake of 12,800 shares — an estimated $333K sold.

A.R.T. Advisors first reported a position in ALLO in Q4 2019 and held it in 1 quarter. The position peaked at $333K in Q4 2019. 115 funds tracked by Wall St. Rank hold ALLO as of Q1 2020.

  • A.R.T. Advisors reported no remaining Allogene Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 12,800 Allogene Therapeutics shares in Q1 2020, an estimated $333K.
  • A.R.T. Advisors first reported a position in Allogene Therapeutics in Q4 2019 and held it in 1 quarter.
  • A.R.T. Advisors's Allogene Therapeutics position peaked at $333K in Q4 2019.
  • 115 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.